Drug intelligence / Profile preview

candonilimab + bevacizumab

Development stage: Unknown
Lead developer: Akeso
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Candonilimab + bevacizumab is a combination therapy being evaluated for the treatment of advanced hepatocellular carcinoma (HCC). Candonilimab (AK104) is a first-in-class humanized tetravalent bispecific antibody that simultaneously targets programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Bevacizumab is a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), thereby inhibiting angiogenesis. This combination is specifically being investigated in a Phase 2 trial (NCT05604391) led by Shi Ming at Sun Yat-sen University as a second-line treatment for patients with advanced HCC who have progressed on the standard-of-care atezolizumab plus bevacizumab regimen. The therapy aims to leverage the synergistic effects of dual immune checkpoint blockade and anti-angiogenic activity to overcome resistance in advanced liver cancer.

Brand names: KaitaniAvastin
Other names: AK104 plus bevacizumabAK-104 plus bevacizumabAK 104 plus bevacizumab

Targets

VEGFA (Vascular endothelial growth factor A)PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)

Beyond the preview

Go deeper on candonilimab + bevacizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on candonilimab + bevacizumab.

Explore the full profile